MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration

MACROGENICS INC

MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.
MacroGenics confirms cash runway guidance into 2026, supported by the $100M milestone plus expected partner payments and product revenues.
Total milestones achieved from Incyte now reach $215M since the initial 2017 collaboration.
Retifanlimab (ZYNYZ) is a PD-1 inhibitor for Merkel cell carcinoma, originally developed by MacroGenics and licensed to Incyte.
MacroGenics remains eligible for up to $210M in development/regulatory milestones and $330M in commercial milestones from Incyte.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.